Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | AML: mutant IDH1 inhibitor HMS-101

Michael Heuser • 25 Oct 2019
COSTEM 2019
Acute Myeloid Leukemia Leukemia HMS-101

Michael Heuser, MD, Hannover Medical School, Hannover, Germany, discusses the aims, methods and findings of his study of the in vivo efficacy of the mutant IDH1 inhibitor HMS-101 and the structural resolution of a distinct binding site. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Michael Heuser

3:01
BAY1436032: IDH1 inhibition in IDH1-mutated AML
Michael Heuser • 2 Jun 2020
3:13
Final results of BRIGHT AML 1003
Michael Heuser • 12 Jun 2020
3:13
Is MRD monitoring prior to allograft standard in AML?
Michael Heuser • 25 Oct 2019
1:30
The clinical application of MRD testing in AML
Michael Heuser • 1 Jun 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals